ConductScience.org, home

Paper41018201

Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus.

Luo L and 5 others. Front Neurol, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus. Papers, record 41018201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41018201

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Therapeutic advances in type 1 myotonic dystrophy complicated with type 2 diabetes mellitus.
PubMed
Journal
Front Neurol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-10-01
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Luo LLin
2Zhu CChangsen
3Yang SShaona
4Sun YYuan
5Rong MMuyang
6Li TTianrong

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References167

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118834994A cross-sectional study for glucose intolerance of myotonic dystrophy.J Neurol Sci2009https://conductscience.org/library/papers/18834994PubMed
224126227The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes.Endocr Pract2013https://conductscience.org/library/papers/24126227PubMed
329289451Mitochondrial dysfunction in myotonic dystrophy type 1.Neuromuscul Disord2018https://conductscience.org/library/papers/29289451PubMed
429404559Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1.JAMA Neurol2018https://conductscience.org/library/papers/29404559PubMed
531479430Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice.J Clin Invest2019https://conductscience.org/library/papers/31479430PubMed
632637445Unexpected Mutations by CRISPR-Cas9 CTG Repeat Excision in Myotonic Dystrophy and Use of CRISPR Interference as an Alternative Approach.Mol Ther Methods Clin Dev2020https://conductscience.org/library/papers/32637445PubMed
734172001Late-onset neuromuscular disorders in the differential diagnosis of sarcopenia.BMC Neurol2021https://conductscience.org/library/papers/34172001PubMed
830182324Cancer incidence among Finnish people with type 2 diabetes during 1989-2014.Eur J Epidemiol2019https://conductscience.org/library/papers/30182324PubMed
936002078Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities.Pharmacol Ther2022https://conductscience.org/library/papers/36002078PubMed
1028129118CRISPR/Cas9-Induced (CTG⋅CAG)n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing.Mol Ther2017https://conductscience.org/library/papers/28129118PubMed
1111528389Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.Nat Genet2001https://conductscience.org/library/papers/11528389PubMed
1221812507Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.Drugs2011https://conductscience.org/library/papers/21812507PubMed
1325753670Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.Nucleic Acids Res2015https://conductscience.org/library/papers/25753670PubMed
1416864839Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2).Neurology2006https://conductscience.org/library/papers/16864839PubMed
1532310829Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin.Aging (Albany NY)2020https://conductscience.org/library/papers/32310829PubMed
1621748485Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias.Diabetologia2011https://conductscience.org/library/papers/21748485PubMed
1725121518Myotonic dystrophy: diagnosis, management and new therapies.Curr Opin Neurol2014https://conductscience.org/library/papers/25121518PubMed
18521833Myotonic dystrophy associated with thyroid disease.J Neurol Sci1979https://conductscience.org/library/papers/521833PubMed
1930053870Dissimilar impact of type 2 diabetes on cardiovascular outcomes according to age categories: a nationwide population study from Hungary.Cardiovasc Diabetol2018https://conductscience.org/library/papers/30053870PubMed
2031045770Clinical implication of maximal voluntary ventilation in myotonic muscular dystrophy.Medicine (Baltimore)2019https://conductscience.org/library/papers/31045770PubMed

See all 167 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41018201

GET https://conductscience.org/api/papers/v1/41018201/references?page=2